0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biosimilar Insulin Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-13W9321
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Biosimilar Insulin Market Insights and Forecast to 2028
BUY CHAPTERS

Global Biosimilar Insulin Market Research Report 2025

Code: QYRE-Auto-13W9321
Report
March 2025
Pages:79
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Biosimilar Insulin Market Size

The global market for Biosimilar Insulin was valued at US$ 3329 million in the year 2024 and is projected to reach a revised size of US$ 8329 million by 2031, growing at a CAGR of 14.2% during the forecast period.

Biosimilar Insulin Market

Biosimilar Insulin Market

Biosimilar insulin is a biological copy of an original insulin and there is increasing interest in developing and using them. Biosimilar insulins (hereafter called biosimilars or follow-on biologics) are designed to be highly similar to the original, or reference, insulin product described in a patent. They are analogous to generic versions of small-molecule drugs and are developed by companies other than the reference product"s patent holder. Producers of biosimilars use manufacturing techniques that are similar, but likely not identical to, those used by the original patent holder. Thus, although a biosimilar and its reference insulin product will have the same amino acid sequence, they may differ slightly in their more subtle molecular characteristics and clinical profiles.
Global Biosimilar Insulin key players include Biocon, Gan&Lee, Wockhardt, Eli Lilly, Sanofi etc. Global top three players hold a share over 70%. India is the largest market, with a share about 30%, followed by Southeast Asia and China, both have a share about 40 percent

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biosimilar Insulin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilar Insulin.
The Biosimilar Insulin market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biosimilar Insulin market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilar Insulin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.

Scope of Biosimilar Insulin Market Report

Report Metric Details
Report Name Biosimilar Insulin Market
Accounted market size in year US$ 3329 million
Forecasted market size in 2031 US$ 8329 million
CAGR 14.2%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Distribution Channel
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Biosimilar Insulin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Biosimilar Insulin in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Biosimilar Insulin Market growing?

Ans: The Biosimilar Insulin Market witnessing a CAGR of 14.2% during the forecast period 2025-2031.

What is the Biosimilar Insulin Market size in 2031?

Ans: The Biosimilar Insulin Market size in 2031 will be US$ 8329 million.

What is the market share of major companies in Biosimilar Insulin Market?

Ans: Global top three players hold a share over 70%.

Who are the main players in the Biosimilar Insulin Market report?

Ans: The main players in the Biosimilar Insulin Market are Eli Lilly, Sanofi, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon, Wockhardt

What are the Type segmentation covered in the Biosimilar Insulin Market report?

Ans: The Types covered in the Biosimilar Insulin Market report are Biosimilar Insulin Glargine, Biosimilar Insulin Lispro, Other

Recommended Reports

Diabetes Drugs

Biosimilar Markets

Insulin and Devices

1 Biosimilar Insulin Market Overview
1.1 Product Definition
1.2 Biosimilar Insulin by Type
1.2.1 Global Biosimilar Insulin Market Value Comparison by Type (2024 VS 2031)
1.2.2 Biosimilar Insulin Glargine
1.2.3 Biosimilar Insulin Lispro
1.2.4 Other
1.3 Biosimilar Insulin by Distribution Channel
1.3.1 Global Biosimilar Insulin Market Value by Distribution Channel (2024 VS 2031)
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Others
1.4 Global Biosimilar Insulin Market Size Estimates and Forecasts
1.4.1 Global Biosimilar Insulin Revenue 2020-2031
1.4.2 Global Biosimilar Insulin Sales 2020-2031
1.4.3 Global Biosimilar Insulin Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Biosimilar Insulin Market Competition by Manufacturers
2.1 Global Biosimilar Insulin Sales Market Share by Manufacturers (2020-2025)
2.2 Global Biosimilar Insulin Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Biosimilar Insulin Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Biosimilar Insulin, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biosimilar Insulin, Product Type & Application
2.7 Global Key Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
2.8 Global Biosimilar Insulin Market Competitive Situation and Trends
2.8.1 Global Biosimilar Insulin Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Biosimilar Insulin Players Market Share by Revenue
2.8.3 Global Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Biosimilar Insulin Market Scenario by Region
3.1 Global Biosimilar Insulin Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Biosimilar Insulin Sales by Region: 2020-2031
3.2.1 Global Biosimilar Insulin Sales by Region: 2020-2025
3.2.2 Global Biosimilar Insulin Sales by Region: 2026-2031
3.3 Global Biosimilar Insulin Revenue by Region: 2020-2031
3.3.1 Global Biosimilar Insulin Revenue by Region: 2020-2025
3.3.2 Global Biosimilar Insulin Revenue by Region: 2026-2031
3.4 North America Biosimilar Insulin Market Facts & Figures by Country
3.4.1 North America Biosimilar Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Biosimilar Insulin Sales by Country (2020-2031)
3.4.3 North America Biosimilar Insulin Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biosimilar Insulin Market Facts & Figures by Country
3.5.1 Europe Biosimilar Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Biosimilar Insulin Sales by Country (2020-2031)
3.5.3 Europe Biosimilar Insulin Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biosimilar Insulin Market Facts & Figures by Region
3.6.1 Asia Pacific Biosimilar Insulin Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Biosimilar Insulin Sales by Region (2020-2031)
3.6.3 Asia Pacific Biosimilar Insulin Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biosimilar Insulin Market Facts & Figures by Country
3.7.1 Latin America Biosimilar Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Biosimilar Insulin Sales by Country (2020-2031)
3.7.3 Latin America Biosimilar Insulin Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biosimilar Insulin Market Facts & Figures by Country
3.8.1 Middle East and Africa Biosimilar Insulin Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Biosimilar Insulin Sales by Country (2020-2031)
3.8.3 Middle East and Africa Biosimilar Insulin Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biosimilar Insulin Sales by Type (2020-2031)
4.1.1 Global Biosimilar Insulin Sales by Type (2020-2025)
4.1.2 Global Biosimilar Insulin Sales by Type (2026-2031)
4.1.3 Global Biosimilar Insulin Sales Market Share by Type (2020-2031)
4.2 Global Biosimilar Insulin Revenue by Type (2020-2031)
4.2.1 Global Biosimilar Insulin Revenue by Type (2020-2025)
4.2.2 Global Biosimilar Insulin Revenue by Type (2026-2031)
4.2.3 Global Biosimilar Insulin Revenue Market Share by Type (2020-2031)
4.3 Global Biosimilar Insulin Price by Type (2020-2031)
5 Segment by Distribution Channel
5.1 Global Biosimilar Insulin Sales by Distribution Channel (2020-2031)
5.1.1 Global Biosimilar Insulin Sales by Distribution Channel (2020-2025)
5.1.2 Global Biosimilar Insulin Sales by Distribution Channel (2026-2031)
5.1.3 Global Biosimilar Insulin Sales Market Share by Distribution Channel (2020-2031)
5.2 Global Biosimilar Insulin Revenue by Distribution Channel (2020-2031)
5.2.1 Global Biosimilar Insulin Revenue by Distribution Channel (2020-2025)
5.2.2 Global Biosimilar Insulin Revenue by Distribution Channel (2026-2031)
5.2.3 Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2020-2031)
5.3 Global Biosimilar Insulin Price by Distribution Channel (2020-2031)
6 Key Companies Profiled
6.1 Eli Lilly
6.1.1 Eli Lilly Company Information
6.1.2 Eli Lilly Description and Business Overview
6.1.3 Eli Lilly Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Eli Lilly Biosimilar Insulin Product Portfolio
6.1.5 Eli Lilly Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Company Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi Biosimilar Insulin Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Gan&Lee
6.3.1 Gan&Lee Company Information
6.3.2 Gan&Lee Description and Business Overview
6.3.3 Gan&Lee Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Gan&Lee Biosimilar Insulin Product Portfolio
6.3.5 Gan&Lee Recent Developments/Updates
6.4 Tonghua Dongbao
6.4.1 Tonghua Dongbao Company Information
6.4.2 Tonghua Dongbao Description and Business Overview
6.4.3 Tonghua Dongbao Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Tonghua Dongbao Biosimilar Insulin Product Portfolio
6.4.5 Tonghua Dongbao Recent Developments/Updates
6.5 United Laboratory
6.5.1 United Laboratory Company Information
6.5.2 United Laboratory Description and Business Overview
6.5.3 United Laboratory Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.5.4 United Laboratory Biosimilar Insulin Product Portfolio
6.5.5 United Laboratory Recent Developments/Updates
6.6 Geropharm
6.6.1 Geropharm Company Information
6.6.2 Geropharm Description and Business Overview
6.6.3 Geropharm Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Geropharm Biosimilar Insulin Product Portfolio
6.6.5 Geropharm Recent Developments/Updates
6.7 Biocon
6.7.1 Biocon Company Information
6.7.2 Biocon Description and Business Overview
6.7.3 Biocon Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Biocon Biosimilar Insulin Product Portfolio
6.7.5 Biocon Recent Developments/Updates
6.8 Wockhardt
6.8.1 Wockhardt Company Information
6.8.2 Wockhardt Description and Business Overview
6.8.3 Wockhardt Biosimilar Insulin Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Wockhardt Biosimilar Insulin Product Portfolio
6.8.5 Wockhardt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biosimilar Insulin Industry Chain Analysis
7.2 Biosimilar Insulin Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biosimilar Insulin Production Mode & Process Analysis
7.4 Biosimilar Insulin Sales and Marketing
7.4.1 Biosimilar Insulin Sales Channels
7.4.2 Biosimilar Insulin Distributors
7.5 Biosimilar Insulin Customer Analysis
8 Biosimilar Insulin Market Dynamics
8.1 Biosimilar Insulin Industry Trends
8.2 Biosimilar Insulin Market Drivers
8.3 Biosimilar Insulin Market Challenges
8.4 Biosimilar Insulin Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Biosimilar Insulin Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Biosimilar Insulin Market Value by Distribution Channel (2024 VS 2031) & (US$ Million)
 Table 3. Global Biosimilar Insulin Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Biosimilar Insulin Sales (K Unit) of Key Manufacturers (2020-2025)
 Table 5. Global Biosimilar Insulin Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Biosimilar Insulin Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Biosimilar Insulin Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Biosimilar Insulin Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Biosimilar Insulin, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Biosimilar Insulin, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Biosimilar Insulin, Product Type & Application
 Table 12. Global Key Manufacturers of Biosimilar Insulin, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Biosimilar Insulin by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biosimilar Insulin as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Biosimilar Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Biosimilar Insulin Sales by Region (2020-2025) & (K Unit)
 Table 18. Global Biosimilar Insulin Sales Market Share by Region (2020-2025)
 Table 19. Global Biosimilar Insulin Sales by Region (2026-2031) & (K Unit)
 Table 20. Global Biosimilar Insulin Sales Market Share by Region (2026-2031)
 Table 21. Global Biosimilar Insulin Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Biosimilar Insulin Revenue Market Share by Region (2020-2025)
 Table 23. Global Biosimilar Insulin Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Biosimilar Insulin Revenue Market Share by Region (2026-2031)
 Table 25. North America Biosimilar Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Biosimilar Insulin Sales by Country (2020-2025) & (K Unit)
 Table 27. North America Biosimilar Insulin Sales by Country (2026-2031) & (K Unit)
 Table 28. North America Biosimilar Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Biosimilar Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Biosimilar Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Biosimilar Insulin Sales by Country (2020-2025) & (K Unit)
 Table 32. Europe Biosimilar Insulin Sales by Country (2026-2031) & (K Unit)
 Table 33. Europe Biosimilar Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Biosimilar Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Biosimilar Insulin Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Biosimilar Insulin Sales by Region (2020-2025) & (K Unit)
 Table 37. Asia Pacific Biosimilar Insulin Sales by Region (2026-2031) & (K Unit)
 Table 38. Asia Pacific Biosimilar Insulin Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Biosimilar Insulin Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Biosimilar Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Biosimilar Insulin Sales by Country (2020-2025) & (K Unit)
 Table 42. Latin America Biosimilar Insulin Sales by Country (2026-2031) & (K Unit)
 Table 43. Latin America Biosimilar Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Biosimilar Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Biosimilar Insulin Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Biosimilar Insulin Sales by Country (2020-2025) & (K Unit)
 Table 47. Middle East and Africa Biosimilar Insulin Sales by Country (2026-2031) & (K Unit)
 Table 48. Middle East and Africa Biosimilar Insulin Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Biosimilar Insulin Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Biosimilar Insulin Sales (K Unit) by Type (2020-2025)
 Table 51. Global Biosimilar Insulin Sales (K Unit) by Type (2026-2031)
 Table 52. Global Biosimilar Insulin Sales Market Share by Type (2020-2025)
 Table 53. Global Biosimilar Insulin Sales Market Share by Type (2026-2031)
 Table 54. Global Biosimilar Insulin Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Biosimilar Insulin Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Biosimilar Insulin Revenue Market Share by Type (2020-2025)
 Table 57. Global Biosimilar Insulin Revenue Market Share by Type (2026-2031)
 Table 58. Global Biosimilar Insulin Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Biosimilar Insulin Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Biosimilar Insulin Sales (K Unit) by Distribution Channel (2020-2025)
 Table 61. Global Biosimilar Insulin Sales (K Unit) by Distribution Channel (2026-2031)
 Table 62. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2020-2025)
 Table 63. Global Biosimilar Insulin Sales Market Share by Distribution Channel (2026-2031)
 Table 64. Global Biosimilar Insulin Revenue (US$ Million) by Distribution Channel (2020-2025)
 Table 65. Global Biosimilar Insulin Revenue (US$ Million) by Distribution Channel (2026-2031)
 Table 66. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2020-2025)
 Table 67. Global Biosimilar Insulin Revenue Market Share by Distribution Channel (2026-2031)
 Table 68. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2020-2025)
 Table 69. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2026-2031)
 Table 70. Eli Lilly Company Information
 Table 71. Eli Lilly Description and Business Overview
 Table 72. Eli Lilly Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Eli Lilly Biosimilar Insulin Product
 Table 74. Eli Lilly Recent Developments/Updates
 Table 75. Sanofi Company Information
 Table 76. Sanofi Description and Business Overview
 Table 77. Sanofi Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Sanofi Biosimilar Insulin Product
 Table 79. Sanofi Recent Developments/Updates
 Table 80. Gan&Lee Company Information
 Table 81. Gan&Lee Description and Business Overview
 Table 82. Gan&Lee Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Gan&Lee Biosimilar Insulin Product
 Table 84. Gan&Lee Recent Developments/Updates
 Table 85. Tonghua Dongbao Company Information
 Table 86. Tonghua Dongbao Description and Business Overview
 Table 87. Tonghua Dongbao Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Tonghua Dongbao Biosimilar Insulin Product
 Table 89. Tonghua Dongbao Recent Developments/Updates
 Table 90. United Laboratory Company Information
 Table 91. United Laboratory Description and Business Overview
 Table 92. United Laboratory Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. United Laboratory Biosimilar Insulin Product
 Table 94. United Laboratory Recent Developments/Updates
 Table 95. Geropharm Company Information
 Table 96. Geropharm Description and Business Overview
 Table 97. Geropharm Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Geropharm Biosimilar Insulin Product
 Table 99. Geropharm Recent Developments/Updates
 Table 100. Biocon Company Information
 Table 101. Biocon Description and Business Overview
 Table 102. Biocon Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Biocon Biosimilar Insulin Product
 Table 104. Biocon Recent Developments/Updates
 Table 105. Wockhardt Company Information
 Table 106. Wockhardt Description and Business Overview
 Table 107. Wockhardt Biosimilar Insulin Sales (K Unit), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Wockhardt Biosimilar Insulin Product
 Table 109. Wockhardt Recent Developments/Updates
 Table 110. Key Raw Materials Lists
 Table 111. Raw Materials Key Suppliers Lists
 Table 112. Biosimilar Insulin Distributors List
 Table 113. Biosimilar Insulin Customers List
 Table 114. Biosimilar Insulin Market Trends
 Table 115. Biosimilar Insulin Market Drivers
 Table 116. Biosimilar Insulin Market Challenges
 Table 117. Biosimilar Insulin Market Restraints
 Table 118. Research Programs/Design for This Report
 Table 119. Key Data Information from Secondary Sources
 Table 120. Key Data Information from Primary Sources
 Table 121. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Biosimilar Insulin
 Figure 2. Global Biosimilar Insulin Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Biosimilar Insulin Market Share by Type: 2024 & 2031
 Figure 4. Biosimilar Insulin Glargine Product Picture
 Figure 5. Biosimilar Insulin Lispro Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Biosimilar Insulin Market Value by Distribution Channel (2020-2031) & (US$ Million)
 Figure 8. Global Biosimilar Insulin Market Share by Distribution Channel: 2024 & 2031
 Figure 9. Hospital
 Figure 10. Retail Pharmacy
 Figure 11. Others
 Figure 12. Global Biosimilar Insulin Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Biosimilar Insulin Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Biosimilar Insulin Sales (2020-2031) & (K Unit)
 Figure 15. Global Biosimilar Insulin Average Price (US$/Unit) & (2020-2031)
 Figure 16. Biosimilar Insulin Report Years Considered
 Figure 17. Biosimilar Insulin Sales Share by Manufacturers in 2024
 Figure 18. Global Biosimilar Insulin Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Biosimilar Insulin Players: Market Share by Revenue in Biosimilar Insulin in 2024
 Figure 20. Biosimilar Insulin Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Biosimilar Insulin Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Biosimilar Insulin Sales Market Share by Country (2020-2031)
 Figure 23. North America Biosimilar Insulin Revenue Market Share by Country (2020-2031)
 Figure 24. United States Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Biosimilar Insulin Sales Market Share by Country (2020-2031)
 Figure 27. Europe Biosimilar Insulin Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Biosimilar Insulin Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Biosimilar Insulin Revenue Market Share by Region (2020-2031)
 Figure 35. China Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. China Taiwan Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Latin America Biosimilar Insulin Sales Market Share by Country (2020-2031)
 Figure 45. Latin America Biosimilar Insulin Revenue Market Share by Country (2020-2031)
 Figure 46. Mexico Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Brazil Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Argentina Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Middle East and Africa Biosimilar Insulin Sales Market Share by Country (2020-2031)
 Figure 50. Middle East and Africa Biosimilar Insulin Revenue Market Share by Country (2020-2031)
 Figure 51. Turkey Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. Saudi Arabia Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. UAE Biosimilar Insulin Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Global Sales Market Share of Biosimilar Insulin by Type (2020-2031)
 Figure 55. Global Revenue Market Share of Biosimilar Insulin by Type (2020-2031)
 Figure 56. Global Biosimilar Insulin Price (US$/Unit) by Type (2020-2031)
 Figure 57. Global Sales Market Share of Biosimilar Insulin by Distribution Channel (2020-2031)
 Figure 58. Global Revenue Market Share of Biosimilar Insulin by Distribution Channel (2020-2031)
 Figure 59. Global Biosimilar Insulin Price (US$/Unit) by Distribution Channel (2020-2031)
 Figure 60. Biosimilar Insulin Value Chain
 Figure 61. Channels of Distribution (Direct Vs Distribution)
 Figure 62. Bottom-up and Top-down Approaches for This Report
 Figure 63. Data Triangulation
 Figure 64. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano String